Lanthio Pharma, MorphoSys join forces to develop new therapeutic peptides

As part of the alliance, the companies will employ their respective technologies to constitute diverse lantipeptide-based libraries.

Under the alliance, MorphoSys will also license the LanthioPep technology for drug discovery, invest in Lanthio Pharma under series A financing round as well as have a minority stake in Lanthio Pharma after closure of the transaction.

MorphoSys chief scientific officer Marlies Sproll said therapeutic peptides and especially stapled or constrained peptides address multiple target classes and disease categories currently beyond reach for therapeutic proteins or small molecules.

”The combination of Lanthio Pharma’s platform and our expertise in intelligent library design offers unique opportunities for both companies and that’s what got us excited," Sproll added.

Lanthio Pharma CEO Bart Wuurman said, "In combination with MorphoSys’s outstanding capabilities in generating high-quality protein libraries we are confident that we can bring lantipeptides to the next level,"